Design, synthesis and evaluation of novel monoamine oxidase B (MAO-B) inhibitors with improved pharmacokinetic properties for Parkinson's disease
作者:Chao Yi、Xinchang Liu、Kangzhi Chen、Haiping Liang、Chuanfei Jin
DOI:10.1016/j.ejmech.2023.115308
日期:2023.4
mice were significantly improved compared to our previous candidate and safinamide, indicating that benzofuran moiety is essential for improving PK properties. Moreover, C14 displayed good metabolic stability and brain-blood barrier permeability, as well as favorable in vitro properties. Finally, C14 significantly inhibited MAO-B in the mouse brain. C14 exhibited a potential efficacy for DA deficits
设计、合成并评估了一系列新型 ((benzofuran-5-yl)methyl)pyrrolidine-2-carboxamide 衍生物作为 MAO-B 抑制剂。SAR 研究表明,将苄基醚环化为苯并呋喃环会产生最有效的 MAO-B 抑制剂(IC 50 = 0.037 μM),( 2S , 4S )-4-fluoro-1-((2-(4-fluorophenyl) benzofuran- 5-基)甲基)吡咯烷-2-甲酰胺( C14 )。与我们之前的候选药物和沙非酰胺相比, C14在大鼠和小鼠中的 PK 特性得到显着改善,表明苯并呋喃部分对于改善 PK 特性至关重要。此外,C14表现出良好的代谢稳定性和脑血屏障通透性,以及良好的体外特性。最后,C14显着抑制小鼠大脑中的 MAO-B。C14在 MPTP 诱导的小鼠模型中表现出对 DA 缺陷的潜在功效,并显着增加纹状体中的 DA 浓度。因此,我们确定C14可能是一种有前途的